



Supplementary Figure. S7. B-RAF_i and MEK_i combinatorial treatments lead to strong synergistic growth inhibition of ^{V600E}B-RAF cell lines regardless of concurrent ^{P124S}MEK1 expression. M229 and M238 vector vs. MEK1 stable cell lines were cultured with different levels of doxycycline (ng/ml), treated with constant ratios of B-RAF_i (vemurafenib) and MEK1/2_i (selumetinib), as indicated (μM), and measured for survival after 72h. Relative synergy of indicated drug combinations (expressed as log₁₀ of CI values) is shown. Calculations were made by CalcuSyn software using the method of Chou and Taladay. Interpretation of CI values is summarized as follows: CI < 0.1 (very strong synergy); = 0.1-0.3 (strong synergy); = 0.3-0.7 (synergy); 0.7-0.85 (moderate synergy); = 0.85-0.9 (slight synergy); = 0.90-1.10 (nearly additive); and = 1.10-1.20 (slight antagonism). The relevant correlated Log₁₀ (CI) values are shown as

follow: $\text{Log}_{10}(\text{CI } 0.1) = -1$; $\text{Log}_{10}(\text{CI } 0.3) = -0.5228787452803376$; $\text{Log}_{10}(\text{CI } 0.7) = -0.1549019599857432$, and $\text{Log}_{10}(\text{CI } 0.85) = -0.07058107428570727$.